Skip Navigation LinksHome > Studies > ADNI study  
 

Alzheimer's Disease Neuroimaging Initiative



Enrollment for this study is closed. However the ADNI GO and ADNI 2 studies are open and enrolling. You can access the ADNI 2 page on this link.

The goal of this study is to determine whether imaging of the brain every six months can help predict the onset and monitor the progression of Alzheimer's disease(AD). The imaging methods used are Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scans. In addition to imaging, the study is testing blood, and for some participants, cerebrospinal fluid (from lumbar puncture) to determine if biomarkers can predict and monitor the disease.

The Alzheimer's Disease Neuroimaging Initiative (ADNI) study is in its fourth full year. Enrollment began in September 2005 and closed in August 2007 with 822 participants at 58 academic medical centers across the United States and Canada: 188 with Alzheimer's disease, 405 with mild cognitive impairment (MCI) and 229 with normal memory. Enrollment was achieved at a swift pace; in fact, it was record breaking. Michael Weiner, M.D., professor of medicine, radiology, Psychiatry, and Neurology at the University of California, San Francisco, is directing the study.

The amount of new exciting information has been enormous. For example almost 100 scientific papers concerning ADNI data were presented at the 2008 International Conference on Alzheimer's Disease. ADNI methods are now being used by pharmaceutical companies in their clinical studies of new drugs and the results of ADNI are being used by academic labs and industry to design future treatment studies. ADNI is accomplishing its goal to provide new methods and data which facilitate the testing of new treatments for Alzheimer's.

The expeditious recruitment effort for ADNI would not have been possible without the support, enthusiastic cooperation and active involvement of the study's participants. Without them researchers could not conduct this essential research that we predict will help us identify imaging and biological markers to measure the progression of MCI and the early stages of AD.